Literature DB >> 22622427

Galectin-1 in melanoma biology and related neo-angiogenesis processes.

Véronique Mathieu1, Elisabeth Martin de Lassalle, Jaan Toelen, Thomas Mohr, Akeila Bellahcène, Gwendoline Van Goietsenoven, Tina Verschuere, Caroline Bouzin, Zeger Debyser, Steven De Vleeschouwer, Stefaan Van Gool, Françoise Poirier, Vincent Castronovo, Robert Kiss, Olivier Feron.   

Abstract

Aggressiveness of advanced melanomas relates in part to their marked propensity to develop neoangiogenesis and metastases. Among its numerous pro-cancer roles, galectin (gal)-1 expressed and/or secreted by both cancer and endothelial cells stimulates proliferation and angiogenesis. This study first shows that gal-1 is more highly expressed at both mRNA and protein levels than its congeners in melanomas and particularly in advanced lesions. The roles of gal-1 were further investigated in vivo in the highly proliferating and vascularized pseudometastatic B16F10 mouse melanoma model using stable knockdown B16F10 cells and wild-type versus gal-1 knockout mice, and then in vitro in B16F10 tumoral and lung microvascular cells. Gal-1 depletion in the B16F10 tumor cells but not in the tumor-bearing mice significantly increased melanoma-bearing mice survival. Tumor-derived gal-1 thus seems to have more critical roles than the host-derived one. In fact, gal-1 displays distinct effects on the H-Ras-dependent p53/p21 pathways: in primary lung microvessel endothelial cells, gal-1 seems to be involved in the maintenance of senescent status through the induction of both p53 and p21 while it stimulates B16F10 cancer cell proliferation through a p53/p21 decrease. Altogether, these data point to gal-1 as a potential target to combat melanomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622427     DOI: 10.1038/jid.2012.142

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.

Authors:  Xinqi Wu; Jingjing Li; Erin M Connolly; Xiaoyun Liao; Jing Ouyang; Anita Giobbie-Hurder; Donald Lawrence; David McDermott; George Murphy; Jun Zhou; Matthias Piesche; Glenn Dranoff; Scott Rodig; Margaret Shipp; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2017-05-04       Impact factor: 11.151

2.  Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential.

Authors:  Erika M Yazawa; Jenna E Geddes-Sweeney; Filiberto Cedeno-Laurent; Kempland C Walley; Steven R Barthel; Matthew J Opperman; Jennifer Liang; Jennifer Y Lin; Tobias Schatton; Alvaro C Laga; Martin C Mihm; Abrar A Qureshi; Hans R Widlund; George F Murphy; Charles J Dimitroff
Journal:  J Invest Dermatol       Date:  2015-03-10       Impact factor: 8.551

Review 3.  Galectins in tumor angiogenesis.

Authors:  Arjan W Griffioen; Victor L Thijssen
Journal:  Ann Transl Med       Date:  2014-09

Review 4.  Galectins in cancer: carcinogenesis, diagnosis and therapy.

Authors:  Ali Hasan Ebrahim; Zainab Alalawi; Leonardo Mirandola; Rahman Rakhshanda; Scott Dahlbeck; Diane Nguyen; Marjorie Jenkins; Fabio Grizzi; Everardo Cobos; Jose A Figueroa; Maurizio Chiriva-Internati
Journal:  Ann Transl Med       Date:  2014-09

5.  Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.

Authors:  Isidro Machado; José Antonio López Guerrero; Samuel Navarro; Empar Mayordomo; Katia Scotlandi; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

6.  Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Authors:  Carlos A Orozco; Neus Martinez-Bosch; Pedro E Guerrero; Judith Vinaixa; Tomás Dalotto-Moreno; Mar Iglesias; Mireia Moreno; Magdolna Djurec; Françoise Poirier; Hans-Joachim Gabius; Martin E Fernandez-Zapico; Rosa F Hwang; Carmen Guerra; Gabriel A Rabinovich; Pilar Navarro
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-03       Impact factor: 11.205

Review 7.  Galectin-1 links tumor hypoxia and radiotherapy.

Authors:  Peiwen Kuo; Quynh-Thu Le
Journal:  Glycobiology       Date:  2014-06-27       Impact factor: 4.313

Review 8.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

9.  Delineating the "galectin signature" of the tumor microenvironment.

Authors:  Daniel Compagno; Diego J Laderach; Lucas Gentilini; Felipe M Jaworski; Gabriel A Rabinovich
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  Dual roles of endogenous and exogenous galectin-1 in the control of testicular immunopathology.

Authors:  Cecilia V Pérez; Leticia G Gómez; Gisela S Gualdoni; Livia Lustig; Gabriel A Rabinovich; Vanesa A Guazzone
Journal:  Sci Rep       Date:  2015-07-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.